Female Pattern Hair Loss, Androgenic Alopecia

This retrospective observational study evaluates the outcomes of a multifactorial drinkable nutraceutical combined with oral minoxidil, compared with oral minoxidil monotherapy, in women with female pattern hair loss (FPHL) treated in routine clinical practice. Data were collected from a cohort of women with FPHL (Ludwig or Olsen grade I) who received either oral minoxidil alone or oral minoxidil plus the nutraceutical for 6 months. Outcomes were assessed at baseline and at 6 months. The main assessment was standardized phototrichoscopy in the frontal region. Patient-reported outcomes included a hair-specific adaptation of the Skindex-29 quality-of-life questionnaire and a treatment perception questionnaire. Adverse events were also recorded. The study aims to explore whether adding the nutraceutical to oral minoxidil gives additional benefits in hair density, hair thickness and quality of life compared with oral minoxidil alone.

The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth

This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL). Participants will receive either N1087 or placebo for 24 weeks. The study includes a titration period starting at 0.5 mg and increasing up to 2 mg daily, followed by treatment at the maximum tolerated dose. The primary objective is to assess changes in non-vellus hair density in the target scalp area after 24 weeks. Secondary objectives include changes in terminal hair density, hair thickness, global photographic assessment, quality of life, and participant satisfaction. Safety will be monitored through adverse events, vital signs, and laboratory tests. Approximately 372 participants will be randomized in a 2:1 ratio (N1087 vs. placebo) across about 10 research centers in Brazil.